VIEMED HEALTHCARE, INC. VMD

Healthcare SIC 8090 - Services-Misc Health & Allied Services, NEC NAICS Health Care and Social Assistance › Ambulatory Health Care Services › Outpatient Care Centers › Other Outpatient Care Centers › Kidney Dialysis Centers derived Nasdaq

Viemed Healthcare, Inc. (the "Company" or "Viemed"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology.

Viemed's primary objective is to drive growth by increasing the number of patients served and the level of care provided through its technology-enabled, home-based clinical care and chronic disease management model. Viemed's care programs are designed specifically to treat patients in the home for less total cost and with a superior quality of care. Viemed's services include respiratory disease management (through the rental of various HME devices), neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, the sale of associated supplies, women's health products and services, and healthcare staffing services.

Last close 9.80 2026-10-23
Market cap $373.3M 2026-06-30 share count
52-week range 6.05 - 12.61

Valuation FY2025 figures against the last close

P/S1.4x
P/E26.5x
P/FCF31.3x
EV/EBITDA7.2x
Dividend yield—
Diluted EPS0.37

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $270.3M$224.3M$183.0M$138.8M$117.1M$131.3M$80.3M$64.5M—
Cost of revenue $114.8M$91.1M$70.2M$54.2M$43.7M$51.2M$24.2M$16.7M—
Gross profit $155.5M$133.2M$112.8M$84.7M$73.4M$80.1M$56.0M$47.8M—
R&D $3.0M$3.1M$2.8M$2.7M$2.1M$1.1M$848.0K$0—
SG&A $121.4M$106.2M$87.9M$68.2M$54.9M$52.8M$41.4M$34.3M—
Operating income $22.9M$17.9M$14.3M$8.3M$11.6M$26.8M$8.9M$10.1M—
Pre-tax income $21.8M$16.2M$14.4M$9.0M$12.5M$26.4M$8.8M$9.7M—
Income tax $6.4M$4.8M$4.1M$2.8M$3.4M$5.2M$271.0K$162.0K—
Net income $15.4M$11.4M$10.2M$6.2M$9.1M$31.5M$8.5M$9.5M—
EPS, basic 0.380.290.270.160.230.810.230.25—
EPS, diluted 0.370.280.250.160.220.780.210.24—
Shares, diluted (wtd. avg.) 40.8M40.8M40.4M39.8M40.7M40.5M39.7M39.7M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $13.5M$17.5M$12.8M$16.9M$28.4M$31.0M$13.4M$10.4M$4.6M
Receivables $25.6M$24.9M$18.5M$15.4M$12.8M$12.4M$11.5M$7.9M$10.7M
Inventory $5.0M$4.3M$4.6M$3.6M$2.5M$2.3M$1.4M$1.9M$2.0M
Total current assets $48.5M$52.9M$38.4M$39.7M$47.3M$47.2M$27.8M$18.9M$17.9M
Property, plant and equipment $78.8M$76.3M$73.6M$67.7M—$55.1M$54.8M$25.3M$22.7M
Goodwill $58.9M$33.0M$29.8M$0—————
Other intangibles $1.3M$848.0K$567.0K$0—————
Total assets $199.2M$177.1M$154.9M$117.0M$118.0M$112.6M$82.6M$44.3M$40.7M
Accounts payable ——————$1.7M$252.0K$0
Short-term debt $1.1M$409.0K$1.1M$0$1.5M$1.8M$1.8M$0$0
Total current liabilities $41.1M$37.3M$32.1M$18.9M$17.8M$23.0M$25.9M$15.5M$14.6M
Long-term debt $11.3M$3.6M$6.0M$0$4.3M$5.8M$7.6M$0$0
Total liabilities $55.6M$43.8M$41.0M$19.9M$23.1M$30.9M$38.9M$16.8M$15.9M
Retained earnings $102.9M$89.7M$79.5M$69.8M$73.3M$65.6M$34.1M$23.5M$21.4M
Total equity $141.5M$131.4M$113.9M$97.1M$94.8M$81.7M$43.7M$32.6M$22.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $51.9M$39.1M$45.2M$27.7M$22.5M$35.1M$19.1M$22.4M—
Depreciation and amortisation $28.6M$25.4M$21.9M$15.6M$11.3M$9.6M$6.4M$3.8M—
Stock-based compensation $9.1M$6.3M$5.8M$5.2M$5.2M$4.9M$3.9M$2.7M—
Capital expenditure $40.0M$37.8M$26.1M$22.9M$19.7M$13.0M$13.4M$6.1M—
Investing cash flow -$50.2M-$30.7M-$52.1M-$24.0M-$19.7M-$8.4M-$12.8M-$5.3M—
Financing cash flow -$5.8M-$3.7M$2.8M-$15.3M-$5.3M-$9.1M-$3.3M-$11.8M—
Buybacks $13.2M$0$0$9.6M$0$0$1.5M$1.6M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001729149-26-000022.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 100M 200M 300M Revenue, FY2018: 64.5M Gross profit, FY2018: 47.8M Net income, FY2018: 9.5M Revenue, FY2019: 80.3M Gross profit, FY2019: 56M Net income, FY2019: 8.5M Revenue, FY2020: 131.3M Gross profit, FY2020: 80.1M Net income, FY2020: 31.5M Revenue, FY2021: 117.1M Gross profit, FY2021: 73.4M Net income, FY2021: 9.1M Revenue, FY2022: 138.8M Gross profit, FY2022: 84.7M Net income, FY2022: 6.2M Revenue, FY2023: 183M Gross profit, FY2023: 112.8M Net income, FY2023: 10.2M Revenue, FY2024: 224.3M Gross profit, FY2024: 133.2M Net income, FY2024: 11.4M Revenue, FY2025: 270.3M Gross profit, FY2025: 155.5M Net income, FY2025: 15.4M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $64.5M $80.3M $131.3M $117.1M $138.8M $183.0M $224.3M $270.3M
Gross profit — $47.8M $56.0M $80.1M $73.4M $84.7M $112.8M $133.2M $155.5M
Net income — $9.5M $8.5M $31.5M $9.1M $6.2M $10.2M $11.4M $15.4M

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8090

TickerCompanyMarket capP/ERevenue growth
DVA DAVITA INC. $11.72B 18.7x 6.5%
SHC Sotera Health Co $5.17B 67.0x 5.7%
PGNY Progyny, Inc. $2.22B 44.6x 10.4%
AGL agilon health, inc. $1.51B — -2.1%
BRTX BioRestorative Therapies, Inc. $41.3M — -10.3%
CCEL CRYO CELL INTERNATIONAL INC $35.9M — -1.3%
MGRX MANGOCEUTICALS, INC. $5.0M — -26.0%
MCTA Charming Medical Ltd — — -27.9%